Enzyme‐immunoassay in the diagnosis of hepatitis with emphasis on the detection of “e” antigen (HBeAg)

Waart, M. van der; Snelting, A.; Cichy, Joanna; Wolters, G. H. J.; Schuurs, A.H.W.M.

doi:10.1002/jmv.1890030111

Cited by 39 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Other microbiological and virologic diagnostic tests soon followed, e.g., for hepatitis B "e" (HBe) antigens (27 ), rubella antibodies, toxoplasma antibodies, and in the 1980s, an EIA system for detection of human immunodeficiency virus antibodies.…”

mentioning

confidence: 99%

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

Lequin¹

2005

Clinical Chemistry

1,270

754

View full text Add to dashboard Cite

This brief note addresses the historical background of the invention of the enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA). These assays were developed independently and simultaneously by the research group of Peter Perlmann and Eva Engvall at Stockholm University in Sweden and by the research group of Anton Schuurs and Bauke van Weemen in The Netherlands. Today, fully automated instruments in medical laboratories around the world use the immunoassay principle with an enzyme as the reporter label for routine measurements of innumerable analytes in patient samples. The impact of EIA/ELISA is reflected in the overwhelmingly large number of times it has appeared as a keyword in the literature since the 1970s. Clinicians and their patients, medical laboratories, in vitro diagnostics manufacturers, and worldwide healthcare systems owe much to these four inventors.

show abstract

mentioning

confidence: 99%

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

Lequin¹

2005

Clinical Chemistry

1,270

754

View full text Add to dashboard Cite

show abstract

“…In 1973 Feinstone et al (6) described the demonstration of hepatitis A virus (HAV) and antibody to HAV (anti-HAV) by immune electron microscopy. Since then, different methods, such as complement fixation (18), immune adherence hemagglutination (15,16), solid-phase radioimmunoassay (SPRIA) (7,19), and enzyme-linked immunosorbent assay (ELISA) (10, 12, 20), have been used to detect HAV and anti-HAV.…”

mentioning

confidence: 99%

Detection of immunoglobulin M antibodies to hepatitis A virus by enzyme-linked immunosorbent assay

Møller¹,

Mathiesen²

1979

J Clin Microbiol

View full text Add to dashboard Cite

An enzyme-linked immunosorbent assay for the detection of immunoglobulin M (IgM) antibodies to hepatitis A virus is described. The test uses the principle of binding of IgM antibodies to anti-IgM-coated microtiter plates to determine whether the IgM antibodies attached have specificities for hepatitis A virus. In three patients with hepatitis type A followed up to 12 months, IgM antibodies to hepatitis A virus could be demonstrated from the onset of illness and during the following 2 to 3 months. When acute-phase sera from 48 patients with acute hepatitis were tested, IgM antibodies to hepatitis A virus could only be demonstrated in 18 patients previously classified as type A, whereas 30 patients with type B and non-A non-B hepatitis were negative. IgM antibodies to hepatitis A virus could not be demonstrated in 108 normal sera nor in 55 sera containing rheumatoid factor. These results indicate that the enzyme-linked immunosorbent assay for IgM antibodies to hepatitis A virus is useful in the serodiagnosis of acute hepatitis type A on a single serum sample taken during the acute phase of illness.

show abstract

“…One of the unresolved problems in the manifestation of type-B hepatitis is the phenomenon of HBeAg. "he detection of HBeAg by very sensitive techniques, such as RIA and ELISA gives a clear insight into its manifestation during the clinical course of the illness [van der Waart et al, 1978;Niermeijer et al, 1979;Krugman et al, 1979;Neurath et al, 19791 . HBeAg is detectable in patients' sera in the early clinical phase of the acute type of hepatitis B infection and disappears before HBsAg becomes undetectable.…”

Section: Discussionmentioning

confidence: 99%

Quantitative relationship between HBeAg and DNA polymerase activity in sera from patients with chronic active hepatitis during a three-month period

Heijtink¹,

Waart²,

Weimar³

et al. 1980

J. Med. Virol.

View full text Add to dashboard Cite

In eight patients with biopsy-confirmed chronic active hepatitis (CAH), hepatitis B e antigen (HBeAg) levels and DNA polymerase (DNA-P) activity were assayed three times a week for six weeks and once a week for another six weeks. HBeAg levels were rather constant, whereas DNA-P activity fluctuated. No correlation was observed between the quantities of HBeAg and DNA-P activity. An unexpected fluctuation in DNA-P activity was noted in all patients after an influenza vaccination.

show abstract

Enzyme‐immunoassay in the diagnosis of hepatitis with emphasis on the detection of “e” antigen (HBeAg)

Cited by 39 publications

References 19 publications

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

Detection of immunoglobulin M antibodies to hepatitis A virus by enzyme-linked immunosorbent assay

Quantitative relationship between HBeAg and DNA polymerase activity in sera from patients with chronic active hepatitis during a three-month period

Contact Info

Product

Resources

About